BioSpace News Archive

Drug pricing watchdog ICER issued a draft report on bluebird bio’s gene therapy betibeglogene autotemcel for beta-thalassemia. The report touted the therapy’s cost-effectiveness.

AbbVie and Genmab announced positive topline results from their Phase I/II trial for lymphoma treatment; Sanofi posted positive results from its Phase I/II trial for the treatment of ITP.

The revised operating plan also includes reductions in spending related to general and administrative expenses and investments in its research platform.

Be Biopharma closed a massive $130M financing to further its proprietary autologous and allogeneic BeCM platform and discover therapies for cancer, rare diseases and more.

Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.

The FDA issued new guidance urging drugmakers to submit racial and minority recruitment plans when designing their studies.

Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announced today that an independent retrospective study reported positive two-year clinical outcomes with the Vantage Ankle Fixed Bearing System.

Akron BioProducts, a leading supplier of cGMP-compliant materials and technologies for cell and gene therapy manufacturing, today announced the launch of its Closed System Solutions™ (CSS) product line, aimed at functionally closing critical unit operations in cell and gene therapy manufacturing workflows.

As a fast growing Contract Research Orgnization (CRO) and clinical diagnostics laboratory, iCura Diagnostics has focused its services on advanced diagnostic techonologies such as multiplexing immunofluorescence (IF)/immunohistochemicstry (IHC), Circulating Tumor Cells (CTC), and genomic servcies to promote clinical trials, translational research, and clinica diagnosis.

According to Report Study, the global AI in Drug Discovery Market was valued USD 1.0 billion in 2021 and is set to reach USD 10.80 billion by 2030 and growing at a CAGR of 36% from 2022 to 2030.